Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elafibranor PK in Healthy Japanese and Non-Asian Volunteers
NCT05543369Phase 1Completed
- Sponsor
- Ipsen
- Start
- Sep 2022
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of elafibranor in primary biliary cholangitis (PBC) (2 cohorts), sponsored by Ipsen. Primary endpoints: Area Under the Concentration-time Curve Over the Dosing Interval at Day 18, Maximum Observed Plasma Drug Concentration at Day 18 and 4 more. Started Sep 2022; status: completed.
02
Drugs
elafibranor
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT05543369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05543369.